- Report
- February 2024
- 177 Pages
Global
From €3497EUR$3,600USD£3,016GBP
- Clinical Trials
- April 2024
- 250 Pages
Global
From €2914EUR$3,000USD£2,514GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1943EUR$2,000USD£1,676GBP
- Report
- February 2024
- 114 Pages
Global
From €4128EUR$4,250USD£3,561GBP
- Report
- March 2024
- 181 Pages
Global
From €3277EUR$3,374USD£2,827GBP
€3641EUR$3,749USD£3,141GBP
- Report
- December 2023
- 150 Pages
Global
From €3529EUR$3,633USD£3,044GBP
€5041EUR$5,190USD£4,349GBP
- Drug Pipelines
- April 2024
- 60 Pages
Global
From €1943EUR$2,000USD£1,676GBP
- Report
- January 2024
- 145 Pages
Global
From €7722EUR$7,950USD£6,661GBP
- Report
- October 2023
- 496 Pages
Global
From €2428EUR$2,500USD£2,095GBP
- Clinical Trials
- January 2024
- 454 Pages
Global
From €2428EUR$2,500USD£2,095GBP
- Report
- June 2023
- 430 Pages
Global
From €2428EUR$2,500USD£2,095GBP
- Report
- July 2023
- 260 Pages
Global
From €2380EUR$2,450USD£2,053GBP
- Report
- April 2024
- 181 Pages
Global
From €4808EUR$4,950USD£4,147GBP
- Report
- February 2024
- 175 Pages
Global
From €4856EUR$5,000USD£4,189GBP
- Report
- November 2023
- 190 Pages
Global
From €4759EUR$4,900USD£4,106GBP
- Report
- February 2024
- 110 Pages
Global
From €4614EUR$4,750USD£3,980GBP
- Report
- February 2024
- 120 Pages
Asia Pacific
From €4808EUR$4,950USD£4,147GBP
- Report
- February 2024
- 120 Pages
Asia Pacific
From €4808EUR$4,950USD£4,147GBP
- Report
- January 2022
- 191 Pages
Global
From €4128EUR$4,250USD£3,561GBP
- Report
- October 2020
- 60 Pages
Global
From €959EUR$988USD£827GBP
€1918EUR$1,975USD£1,655GBP
The Pulmonary Fibrosis Drug market is a subset of the larger Respiratory Drugs market. It is composed of drugs used to treat pulmonary fibrosis, a chronic and progressive lung disease. These drugs are used to reduce symptoms, slow the progression of the disease, and improve quality of life. Common treatments include corticosteroids, immunosuppressants, and antifibrotic agents. In some cases, lung transplantation may be recommended.
The Pulmonary Fibrosis Drug market is highly competitive, with many companies developing and marketing treatments. Some of these companies include Boehringer Ingelheim, Gilead Sciences, GlaxoSmithKline, Novartis, and Vertex Pharmaceuticals. Show Less Read more